CL2022003532A1 - Anticuerpos para btla - Google Patents

Anticuerpos para btla

Info

Publication number
CL2022003532A1
CL2022003532A1 CL2022003532A CL2022003532A CL2022003532A1 CL 2022003532 A1 CL2022003532 A1 CL 2022003532A1 CL 2022003532 A CL2022003532 A CL 2022003532A CL 2022003532 A CL2022003532 A CL 2022003532A CL 2022003532 A1 CL2022003532 A1 CL 2022003532A1
Authority
CL
Chile
Prior art keywords
antibodies
btla
bind
human
relates
Prior art date
Application number
CL2022003532A
Other languages
English (en)
Inventor
Simon John Davis
Richard John Cornall
Christopher Douglas Paluch
Original Assignee
Univ Oxford Innovation Ltd
Mirobio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd, Mirobio Ltd filed Critical Univ Oxford Innovation Ltd
Publication of CL2022003532A1 publication Critical patent/CL2022003532A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Esta invención se relaciona generalmente con anticuerpos que se unen al atenuador de linfocitos B y T (BTLA) humano y usos de estos. Más específicamente, la invención se relaciona con anticuerpos agonistas que se unen a BTLA humano y modulan su actividad, y su uso en el tratamiento de enfermedades y trastornos inflamatorios, autoinmunitarios y proliferativos. Adecuadamente, los anticuerpos también tienen una modificación de Fc que mejora la señalización a través de Fc?R2B.
CL2022003532A 2020-06-11 2022-12-12 Anticuerpos para btla CL2022003532A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2008860.5A GB202008860D0 (en) 2020-06-11 2020-06-11 BTLA antibodies

Publications (1)

Publication Number Publication Date
CL2022003532A1 true CL2022003532A1 (es) 2023-08-11

Family

ID=71835530

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003532A CL2022003532A1 (es) 2020-06-11 2022-12-12 Anticuerpos para btla

Country Status (18)

Country Link
US (1) US20230235058A1 (es)
EP (1) EP4165080A2 (es)
JP (2) JP7486616B2 (es)
KR (1) KR20230031891A (es)
CN (1) CN116234826A (es)
AR (1) AR122605A1 (es)
AU (1) AU2021287338A1 (es)
BR (1) BR112022025259A2 (es)
CA (1) CA3186728A1 (es)
CL (1) CL2022003532A1 (es)
CO (1) CO2022017976A2 (es)
CR (1) CR20220635A (es)
DO (1) DOP2022000285A (es)
GB (1) GB202008860D0 (es)
IL (1) IL298973A (es)
MX (1) MX2022015798A (es)
TW (1) TW202214693A (es)
WO (1) WO2021250419A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024020407A1 (en) * 2022-07-19 2024-01-25 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU716785B2 (en) 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
EP1919950A1 (en) 2004-07-15 2008-05-14 Xencor, Inc. Optimized fc variants
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
EP2708557A1 (en) 2007-05-30 2014-03-19 Xencor, Inc. Method and compositions for inhibiting CD32B expressing cells
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
EP2459594A1 (en) 2009-07-31 2012-06-06 N.V. Organon Fully human antibodies to btla
MX353144B (es) 2010-04-20 2017-12-20 Genmab As Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
JP2018521959A (ja) 2015-04-29 2018-08-09 サンフォード−バーナム メディカル リサーチ インスティテュート Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション
AU2016286108B2 (en) 2015-06-30 2021-03-11 Pfizer Inc. BTLA fusion protein agonists and uses thereof
JOP20190261A1 (ar) 2017-05-19 2019-11-05 Lilly Co Eli أجسام مضادة لعامل مساعد لـ btla واستخداماتها
GB201820554D0 (en) 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies

Also Published As

Publication number Publication date
CR20220635A (es) 2023-07-07
CO2022017976A2 (es) 2023-04-27
BR112022025259A2 (pt) 2023-01-31
DOP2022000285A (es) 2023-04-30
AR122605A1 (es) 2022-09-21
KR20230031891A (ko) 2023-03-07
CN116234826A (zh) 2023-06-06
WO2021250419A2 (en) 2021-12-16
JP2024073580A (ja) 2024-05-29
JP7486616B2 (ja) 2024-05-17
GB202008860D0 (en) 2020-07-29
CA3186728A1 (en) 2021-12-16
MX2022015798A (es) 2023-03-23
TW202214693A (zh) 2022-04-16
EP4165080A2 (en) 2023-04-19
WO2021250419A3 (en) 2022-02-17
AU2021287338A1 (en) 2023-02-02
IL298973A (en) 2023-02-01
JP2023529215A (ja) 2023-07-07
US20230235058A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
CO2021003724A2 (es) Proteínas de fijación a sirpα y métodos de uso de estas
CL2022003532A1 (es) Anticuerpos para btla
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
CO2018014010A2 (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
CO2021006663A2 (es) Anticuerpos anti-npr1 y su uso
CO2018003852A2 (es) Proteínas de unión a antigeno que activan el receptor de leptina
CL2018000103A1 (es) Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
WO2020128446A3 (en) Anti-btla antibodies
CL2021003266A1 (es) Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
CL2019003392A1 (es) Proteínas de anticuerpo injertadas con citocinas y métodos de uso para trastornos relacionados con el sistema inmunitario.
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
ECSP22041860A (es) Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso
CO2021006953A2 (es) Anticuerpos anti-claudina 18.2 y anti-4-1bb bispecificos y su uso
AR117565A1 (es) Agentes de unión a c3 y método de uso de los mismos
AR111752A1 (es) Anticuerpos agonistas contra el atenuador de linfocitos b y t (btla) y sus usos
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
CO2023012821A2 (es) Anticuerpos anti-nectina-4 y usos de los mismos
BR112021024507A2 (pt) Agonista de pd-1 e método de uso do mesmo
BR112021000899A2 (pt) Peptídeos de ligação a il-17a e usos médicos dos mesmos
CO2022004743A2 (es) Anticuerpos dirigidos a flt3 y uso de los mismos
AR120077A1 (es) ANTICUERPOS ANTI-TGF-b 1 LATENTE Y MÉTODOS DE USO
CL2022001546A1 (es) Formulaciones líquidas de tasimelteón y métodos para su uso
BR112021013206A2 (pt) Bibliotecas de peptídeos e respectivos métodos de uso
CL2023000216A1 (es) Anticuerpos anti-abeta